Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial

BACKGROUND: Human African trypanosomiasis caused by Trypanosoma brucei gambiense (gambiense HAT) in patients with late-stage disease requires hospital admission to receive nifurtimox–eflornithine combination therapy (NECT). Fexinidazole, the latest treatment that has been recommended by WHO, also re...

Descripción completa

Detalles Bibliográficos
Autores principales: Betu Kumeso, Victor Kande, Kalonji, Wilfried Mutombo, Rembry, Sandra, Valverde Mordt, Olaf, Ngolo Tete, Digas, Prêtre, Adeline, Delhomme, Sophie, Ilunga Wa Kyhi, Médard, Camara, Mamadou, Catusse, Julie, Schneitter, Stefan, Nusbaumer, Morgane, Mwamba Miaka, Erick, Mahenzi Mbembo, Hélène, Makaya Mayawula, Joseph, Layba Camara, Mariame, Akwaso Massa, Félix, Kaninda Badibabi, Lewis, Kasongo Bonama, Augustin, Kavunga Lukula, Papy, Mutanda Kalonji, Sylvain, Mariero Philemon, Phyll, Mokilifi Nganyonyi, Ricardo, Embana Mankiara, Hugues, Asuka Akongo Nguba, André, Kobo Muanza, Vincent, Mulenge Nasandhel, Ernest, Fifi Nzeza Bambuwu, Aimée, Scherrer, Bruno, Strub-Wourgaft, Nathalie, Tarral, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science ;, The Lancet Pub. Group 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033454/
https://www.ncbi.nlm.nih.gov/pubmed/36460027
http://dx.doi.org/10.1016/S1473-3099(22)00660-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033454/
https://www.ncbi.nlm.nih.gov/pubmed/36460027
http://dx.doi.org/10.1016/S1473-3099(22)00660-0

Ejemplares similares